The ability of cancer cells to survive and grow under hypoxic conditions has been known for decades, but the mechanisms remain poorly understood. Under certain conditions, cancer cells undergo changes in their bioenergetic profile to favor mitochondrial respiration by activating the peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1a) and up-regulating mitochondrial biogenesis. In this study, we hypothesized that augmented mitochondrial biogenesis plays a critical role for cancer cells to survive hypoxia. Consistent with this hypothesis, both hypoxic human hepatocellular carcinoma (HCC) tumors and HCC cell lines subjected to hypoxia increase mitochondrial biogenesis. Silencing of PGC-1a in hypoxic HCC cell lines halts their proliferation. Mechanistic investigations in vitro indicated that intracellular high mobility group box 1 (HMGB1) protein, a nuclear protein overexpressed in HCC, is essential for the process. Silencing of HMGB1 in hypoxic HCC cell lines resulted in a significant decrease in PGC-1a activation and mitochondrial biogenesis. Without HMGB1, hypoxic HCC cells had significantly reduced adenosine triphosphate production, decreased cellular proliferation, and increased apoptosis. In a diethylnitrosamine-induced murine model of HCC, genetic blocking of HMGB1 in hypoxic tumors resulted in a significant decrease in tumor growth. Tumors lacking HMGB1 had a significant reduction in mitochondrial biogenesis and a significant increase in mitochondrial dysfunction. Further in vitro mechanistic experiments indicated that during hypoxia HMGB1 translocates from the nucleus to the cytoplasm and binds to cytoplasmic Toll-like receptor-9. This binding leads to activation of p38 and subsequent phosphorylation of PGC-1a, with resultant up-regulation of mitochondrial biogenesis. Conclusion: Taken together, our findings suggest that during hypoxia HMGB1 up-regulates mitochondrial biogenesis in HCC cancer cells, promoting tumor survival and proliferation. (HEPATOLOGY 2017;66:182-197).
H epatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. (1) The incidence in the United States is rising, and the overall 5-year survival is only 16%. Reasons for this poor prognosis include severe underlying liver disease, delay in diagnosis, and the lack of effective therapy. (2) But, most importantly, the dismal outcomes are closely related to the aggressive and highly proliferative capacity of HCC cells, (3) which has, in turn, been linked to the continuous oxidative stress and chronic Abbreviations: Alb, albumin; Alb-HMGB1 -/-, hepatocyte-specific HMGB1 knockout; ATP, adenosine triphosphate; DEN, diethylnitrosamine; HCC, hepatocellular carcinoma; HIF1a, hypoxia-inducible factor 1 alpha; HMGB1, high mobility group box-1; 4-HNE, 4-hydroxynonenal; mtDNA, mitochondrial DNA; NRF1, nuclear respiratory factor-1; OCR, oxygen consumption rate; PGC-1a, peroxisome proliferator-activated receptor gamma coactivator 1 alpha; ROS, reactive oxygen species; siRNA, small interfering RNA; Tfam, transcription factor A, mitochondrial; TLR, Toll-like receptor; TOM20, translocase of outer membrane 20. inflammation generated in the hepatic tumor microenvironment. (4) In HCC, regions of hypoxia are commonly found throughout the rapidly growing tumor with areas of necrosis, irregular blood flow, and poor oxygen diffusion. (5, 6) The link between hypoxia and tumor progression has long been recognized. Indeed, the extent of tumor hypoxia has been shown to confer worse prognosis in patients with solid tumors, (7) but mechanisms by which HCC tumors thrive despite the harsh hypoxic microenvironment remain incompletely understood.
It has long been accepted that dividing cancer cells meet their metabolic demands through the "Warburg effect," the process of aerobic glycolysis. (8, 9) The energy generated through aerobic glycolysis was once thought to be sufficient to supply the anabolic energy demands of a rapidly dividing cancer cell. (8, 9) More recently, however, cancer cells have been shown to supplement the energy provided by aerobic glycolysis by upregulating mitochondrial respiration for a major fraction of their adenosine triphosphate (ATP). (10) Thus, cancer cells seem to have the capacity to reprogram their bioenergetic profiles in response to unfavorable microenvironmental conditions. (10) (11) (12) (13) In fact, cancer cells in the process of metastasis and invasion exhibit down-regulation of glycolysis pathways and enhanced oxidative phosphorylation by inducing mitochondrial biogenesis. (13) Whether HCC growth under severe hypoxic conditions depends on mitochondrial biogenesis is unknown.
Mitochondrial biogenesis is a potential alternative for cancer cells to employ to reprogram their metabolic pathways under adverse conditions. Mitochondrial biogenesis would allow the cancer cells to increase oxidative phosphorylation in mitochondria by growth and division of existing mitochondria. Even though evidence shows that metabolic reprogramming toward oxidative phosphorylation and mitochondrial biogenesis is important for metastasis (13) and tumor growth, (11) the exact mechanisms governing it remain unclear. High mobility group box 1 (HMGB1) is a highly conserved DNA-binding nuclear protein that acts as a damage-associated molecular pattern protein in response to stress. (14) HMGB1 plays a major role in conditions of inflammation accompanied by mitochondrial abnormalities, including neurodegeneration, aging, and cancer. (15) HMGB1 is overexpressed in HCC tumors and serum of patients with HCC. (16) The hypoxic environment generated in solid tumors, including HCC, induces the translocation of HMGB1 from the nucleus of tumor cells to the cytoplasm and thence to the extracellular space. (6, 16) We have shown that cytoplasmic HMGB1 activates Toll-like receptor (TLR)-9 in hypoxic HCC cells and that the interaction is critical for cancer cell proliferation and survival under stressful conditions. (6) TLR9 is an endosomal receptor that is widely overexpressed in many tumors including HCC where hypoxia is common, and it is also overexpressed in HCC cell lines subjected to hypoxia. (6, 17, 18) Of interest, TLR9 has been shown to be important in inducing mitochondrial biogenesis in hepatocytes under experimental septic conditions. (19) Whether HMGB1/TLR9 interactions in hypoxic cancer cells can also foster mitochondrial biogenesis and possibly enhance tumor growth has not been studied.
In this study we demonstrate that HCC cells adapt to hypoxic conditions by up-regulating their mitochondrial biogenesis. During hypoxia, HMGB1 quickly translocates to the cytosol and interacts with TLR9. The activation of TLR9 results in triggering the
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signaling cascade involved in mitochondrial biogenesis, with subsequent increased cancer proliferation under harsh hypoxic conditions both in vitro and in vivo.
Materials and Methods

PATIENT SAMPLES AND CELL LINES
All human materials used were obtained under an approved institutional review board protocol. Written informed consent was received from all participants prior to inclusion. Tumor and adjacent nontumor tissues were collected from patients undergoing surgery for HCC at the University of Pittsburgh. Hepa-1-6 and Huh7 cell lines were purchased from ATCC (Manassas, VA). Cell lines were amplified in our lab and stored in liquid nitrogen to ensure that cells used for experiments were passaged for fewer than 6 months. Cell lines were tested biannually for identity by appearance and growth curve analysis and validated to be mycoplasma-free. Cancer cells were transferred to a hypoxia chamber (1% O 2 ) when needed.
ANIMALS
Animal protocols were approved by the institutional Animal Care and Use Committee and adhered to the National Institutes of Health guidelines. Male wildtype (HMGB1 loxP/loxP ) mice and hepatocyte HMGB1-depleted (Alb-HMGB1 -/-) mice were bred at our facility. All mice developed were on a C57BL/6 genetic background. Generation of control mice (HMGB1 loxP/loxP ) and Alb-HMGB1 -/-mice and the confirmation and characterization of the mice are described in detail in our previous work. (20) Briefly, the HMGB1 loxP allele was created by inserting loxP sites within introns 1 and 2, flanking exon 2 of HMGB1. Homozygous HMGB1 loxP mice were generated using Ozgene (Bently, WA). HMGB1 loxP/loxP mice were interbred with stud males (HMGB1 loxP/-;Alb-cre ) to generate the desired phenotype. Mice homozygous for Cre recombinase linked to the albumin (alb) promoter are commercially available from Jackson.
DIETHYLNITROSAMINE MODEL OF MURINE HCC
Two week-old male pups, control (HMGB1 loxP/loxP ) and Alb-HMGB1 -/-, were injected with diethylnitrosamine (DEN) 25 mg/kg (in 0.9% saline) intraperitoneally. Mice were sacrificed 6 months later, and the livers were harvested for analysis.
SILENCING OF HMGB1 AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA COACTIVATOR 1 ALPHA IN CANCER CELLS HMGB1 and peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1a) small interfering RNA (siRNA; Santa Cruz Biotechnology) were transfected into cancer cells using transfection reagent (Santa Cruz) according to the manufacturer's instruction. Control sequences purchased from Santa Cruz were included as a negative control. After 48 hours, cells were collected and treated accordingly.
MEASUREMENT OF OXYGEN CONSUMPTION RATE
Cancer cells were plated in XF96 cell culture (Seahorse Bioscience) microplates at the density of 10K/well, with a total volume of 200 lL/well. Cells were incubated at 378C overnight and then treated with 24 hours of hypoxia (1% O 2 ). The oxygen consumption rate (OCR) was measured by the XF96e machine. After measurement of basal OCR, cells were treated with 1.0 lM oligomycin, 1.0 lM carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone, and 10 lM rotenone to generate a bioenergetic profile. All rates are shown with the rotenone rate subtracted to correct for nonmitochondrial oxygen consumption. (21) 
ATP MEASUREMENT
Quantification of cellular ATP levels was performed using an ATP assay kit (Abcam) per the manufacturer's instructions. (20) 
MITOCHONDRIAL DNA QUANTIFICATION
Total DNA was harvested from cancer cells using the DNeasy Blood and Tissue Kit. Quantitative PCRs were performed in triplicate using a MicroAmp fast 96-well reaction plate (Applied Biosystems). Each reaction contained 50 ng of DNA, 10 lL of Power SYBER-Green PCR Master Mix (Applied Biosystems), and 1 lL of each sense and antisense primer, with a total of 20 lL/well. The copy number of DNA encoding cytochrome c oxidase I was measured and normalized by mouse b-actin using quantitative realtime PCR.
STATISTICAL ANALYSIS
Results are expressed as either standard error of the mean or mean standard deviation. Group comparisons were performed using one-way analysis of variance with post hoc Tukey honestly significant difference analysis and Student t test. P < 0.05 was considered to be statistically significant. Experimental data were collected from at least three independent experiments to avoid cell culture variation.
Results
HCC CELLS EXHIBIT ENHANCED MITOCHONDRIAL BIOGENESIS DURING HYPOXIA
Some cancer cells can undergo metabolic reprogramming with up-regulation of mitochondrial biogenesis and more reliance on oxidative phosphorylation under certain conditions. (13) PGC-1a is a key transcription coactivator for mitochondrial biogenesis. After translocation to the nucleus, PGC-1a and nuclear respiratory factor 1 (NRF1) control the expression of transcription factor A (Tfam). (22) Tfam then translocates to the mitochondria to initiate mitochondrial DNA replication and biogenesis. We first looked at whether hypoxic HCC cells use this pathway to survive and grow under stress. Hypoxic murine HCC cells, Hepa1-6, and the human HCC cell line Huh7 are able to grow at comparable rates to respective HCC cells at normal conditions despite conditions of hypoxia (Supporting Fig. S1A ). Subjecting HCC cell lines to a time course of hypoxia (1% O 2 ), we observed a time-dependent up-regulation in the expression of PGC-1a, NRF1, and Tfam in both HCC cell lines as evidenced by both western blots (Fig. 1A) and RT-PCR analysis (Fig. 1B) . Of note, there was no significant difference in the expression of PGC-1a when HCC cells were subjected to atmospheric normoxia (21% O 2 ) compared to physioxia (5% O 2 ) (Supporting Fig. S1B ). When PGC-1a was silenced using PGC1a siRNA, there was a significant decrease in the expression of the proteins associated with mitochondrial biogenesis (PGC-1a, NRF1, and Tfam) (Fig.  1C) and a significant reduction in mitochondrial biogenesis as assessed by reduced cellular mitochondrial DNA (mtDNA) content (Fig. 1D) . Following 24 hours of hypoxia, there was a significant increase in mitochondrial density in hypoxic HCC cell lines compared to cells under normoxic culture conditions (Fig.  1E) . When PGC-1a was silenced, there was no increase in mitochondrial density (Fig. 1E) . Intracellular reactive oxygen species (ROS) production, a consequence of mitochondrial dysfunction when biogenesis is impaired, can induce apoptosis in cancer cells. (23) Indeed, there was a significant increase in accumulation of ROS (Supporting Fig. S1C ) and a decrease in proliferation ( Fig. 1F ) of PGC-1a-silenced HCC cell lines subjected to hypoxia compared to HCC cell lines treated with control siRNA.
HMGB1 FACILITATES PGC1-a EXPRESSION AND MITOCHONDRIAL BIOGENESIS IN HYPOXIC CANCER CELLS
We next explored the mechanism behind hypoxiadriven up-regulation of mitochondrial biogenesis. HMGB1 is a nuclear protein that translocates to the cytoplasm in stressed cancer cells and is critical for cancer cell adaptation to hypoxic stress. (6) We, therefore, next examined the role of HMGB1 in up-regulating mitochondrial biogenesis in cancer cells. We compared the expression of HMGB1, PGC-1a, NRF1, Tfam, and hypoxia-inducible factor 1 alpha (HIF1a) in 15 paired human HCC tissue samples and their corresponding nontumor liver tissue by western blot analysis. There was increased expression of HMGB1, PGC-1a, NRF1, and Tfam in hypoxic tumor tissue (expressing HIF1a) compared to nontumor tissue. Two representative pairs of the 15 pairs tested are shown in Fig. 2A . In vitro, we silenced HMGB1 expression in both Hepa1-6 and HuH7 HCC cell lines using mouse and human HMGB1 siRNA (Supporting Fig. S2A ). Western blot, quantitative PCR analyses, and immunofluorescent staining revealed significant down-regulation of PGC-1a, NRF1, and Tfam in hypoxic HCC cells when HMGB1 was silenced ( Fig.  2B-D) . There was no difference in PGC-1a expression between HMGB1 siRNA-treated and control cells under normoxic conditions (Supporting Fig. S2B ). Measurement of mtDNA copies revealed decreased mitochondrial density and thus inability of HMGB1-deficient cancer cells to up-regulate mitochondrial biogenesis under hypoxic stress (Fig. 2E) . Similarly, we found decreased mitochondrial mass in HMGB1-silenced HCC cells by measuring levels of complex IV FIG. 1. HCC cells exhibit enhanced mitochondrial biogenesis during hypoxia. Up-regulation of mitochondrial biogenesis-associated proteins PGC-1a, TFAM, and NRF1 in HCC cancer cell lines Hepa1-6 and Huh7 subjected to a time course of hypoxia as seen by (A) western blot and (B) RT-PCR analysis. *P < 0.05, **P < 0.01, #P < 0.001, comparisons made to control. (C) There was a significant decrease in the expression of the above proteins when PGC-1a was silenced in the hypoxic Hep1-6 cells compared to a scramble control siRNA. (D) mtDNA content in Hep1-6 cells undergoing 24 hours of hypoxia treated with either PGC-1a siRNA or control siRNA compared with control cells under normoxic conditions. **P < 0.01, ***P < 0.001. (E) Mitochondrial density was also measured using confocal microscopy. Mitotracker staining demonstrated increased mitochondrial density in Hepa1-6 cells subjected to 24 hours of hypoxia (0. 
SILENCING HMGB1 EXPRESSION IN HCC CELLS IMPAIRS MITOCHONDRIAL FUNCTIONAL INTEGRITY AND CELL SURVIVAL UNDER HYPOXIC CONDITIONS
We next studied the effect of loss of silencing HMGB1 and its consequent loss of mitochondrial biogenesis on the adaptation of cancer cells to hypoxia. We therefore studied the effect of HMGB1 siRNA on mitochondrial morphology, ATP production, OCR, ROS production, and degree of proliferation and apoptosis of HCC cell lines exposed to hypoxia. Transmission electron microscopy revealed reduced numbers of mitochondria and swollen mitochondria with disorganized cristae, suggesting impaired mitochondrial respiration when HMGB1-deficient cancer cells were subjected to hypoxia (Fig. 3A) . ATP production levels in hypoxic tumor cells fall soon after the onset of hypoxia, then gradually increase to levels comparable to normoxic cancer cells (Fig. 3B) . When HMGB1 is silenced, however, ATP levels do not recover and remain low.
We verified the impaired mitochondrial respiration by measuring OCR in a series of mitochondrial stress tests performed on HMGB1-depleted and control HCC cells using an extracellular flux analyzer. These experiments indicated that mitochondrial respiratory capacity was diminished when HMGB1 was suppressed (Fig. 3C ). Basal respiration rate was significantly decreased in hypoxic HMGB1 siRNA cells compared with control cells. In addition, there was a substantial decrease in maximal capacity (carbonyl cyanide 4-[trifluoromethoxy]phenylhydrazone-stimulated OCR) when HMGB1 was silenced. Of note, we again found no significant changes in basal respiration rate between HMGB1 siRNA cells and control cells under normoxic conditions (Supporting Fig. S2C ). As expected in cells with impaired mitochondrial respiration, flow cytometry (Fig. 3D ) and immunofluorescent staining (Supporting Fig. S2D ) both showed a significant increase in ROS cellular production when HMGB1-silenced cells were stimulated with hypoxia. As a consequence of the metabolic derangements in the absence of HMGB1 and mitochondrial biogenesis, there was a significant decrease in cancer cell proliferation (Fig. 3E ) and a significant increase in apoptosis as seen of flow-cytometric analysis (Fig. 3F ) and increased levels of cleaved caspase 3 (Supporting Fig.  S2E ). Of note, we also found that there was a decrease in the migratory and invasive ability of the HMGB1-deficient cancer cell lines that are not able to upregulate their mitochondrial biogenesis in response to hypoxia (Supporting Fig. S2F ). Similar to HMGB1-depleted cells, when PGC-1a is silenced in Hepa1-6 cells, there is an increased rate of apoptosis in the hypoxic cells (Supporting Fig. S3A ). The mitochondrial respiratory capacity was diminished when PGC-1a was suppressed. Basal respiration rate was significantly decreased in hypoxic PGC-1a siRNA cells compared with control cells. In addition, there was a substantial decrease in maximal capacity (carbonyl cyanide 4-[trifluoromethoxy]phenylhydrazone-stimulated OCR) when PGC-1a was silenced (Supporting Fig. S3B ). Also, ATP levels do not recover and remain low when PGC-1a siRNA-treated cells are subjected to hypoxia compared to control cells (Supporting Fig. S3C ). These experiments indicate that mitochondrial respiratory capacity and mitochondrial biogenesis are diminished when HMGB1 or PGC-1a was suppressed and that this translated into a lesser ability to survive harsh hypoxic stress.
HMGB1 LOSS IN HEPATOCYTE CAUSES DECREASED TUMOR GROWTH IN MICE IN RESPONSE TO DEN
Our above findings demonstrate that HMGB1-induced mitochondrial biogenesis is critical for continued cancer cell survival under conditions of hypoxia in vitro. As hypoxia is prominent in HCC tumors, we next evaluated the in vivo behavior of tumors in the absence of HMGB1. We therefore created hepatocyte-depleted HMGB1 knockout mice using Cre-LoxP technology. (20) Control (HMGB1 loxP/loxP ) and Alb-HMGB1 -/-mice were then subjected to DEN to promote formation of HCC. Both groups developed HCC. Six months after DEN injection, we confirmed that HMGB1 is depleted in both the tumor and nontumor liver tissue in Alb-HMGB1 -/-mice (Fig. 4A ). Figure  4A also shows that HMGB1 is overexpressed in tumor compared to nontumor tissue in HMGB1 control mice. As anticipated, hypoxia was prominent in the tumors of both HMGB1 control and Alb-HMGB1 -/-mice (Fig. 4B) . However, compared to HMGB1 control, Alb-HMGB1 -/-mice exhibited smaller and less numerous tumors (Fig. 4C,D) . In addition, Alb- -/-versus 7.2 6 0.6 nodules in control HMGB1 mice; P < 0.001). Alb-HMGB1 -/-mice had a significant decrease in tumor burden compared to HMGB1 control mice as seen by (E) liver-to-body ratio (48% decrease in Alb-HMGB1 -/-mice, P < 0.001) and (F) percentage hepatic replacement by DEN-induced HCC tumors (mean percentage replacement 6.3 6 1.8% in control versus 55 6 5.5% in Alb-HMGB1 -/-, P < 0.01; area occupied by tumors represented as black dashed line). Data represent mean 6 standard error of the mean; n 5 16 mice/group. The above data are representative of three experiments with similar results. **P < 0.01, ***P < 0.001. Abbreviations: NT, nontumor liver; T, tumor.
HMGB1
-/-mice had significantly decreased tumor load after DEN as evidenced by the liver-to-body weight ratio and the tumor hepatic replacement area (Fig. 4E,F) .
Alb-HMGB1 -/-TUMORS AFTER DEN SHOW DECREASED ADAPTATION TO HYPOXIA AND DECREASED MITOCHONDRIAL BIOGENESIS
Hypoxic DEN-induced HCC tumors in control mice showed significant up-regulation of mitochondrial biogenesis as evidenced by increased expression of PGC1-a compared to normal liver background (Fig.  5A,B) . In contrast, mitochondrial biogenesis pathways were not up-regulated in the slow-growing smaller tumors of Alb-HMGB1 -/-mice (Fig. 5C ). Of note, there was no significant difference in PGC1-a expression in nontumor tissue of control mice compared to Alb-HMGB1 -/-mice (Supporting Fig. S4A,B) . Also, there was no difference in translocase of outer membrane 20 (TOM20) staining between nontumor tissue of control and Alb-HMGB1 -/-mice (Supporting Fig.  S4C ). There was a decrease in mitochondrial density in the hypoxic Alb-HMGB1 -/-tumors with decreased mtDNA copies and decreased staining for mitochondrial marker TOM20 compared to control tumors (Fig.  5D,E) . In addition, there was a decrease in ND1 and cytochrome c oxidase III expression in tumors of Alb-HMGB1 -/-mice compared to controls (Supporting Fig. S5A ). Moreover, there was a significant decrease in the expression of PGC-1a, NRF, and TFAM in Alb-HMGB1 -/-tumors compared to control (Supporting Fig. S5B,C) .
To examine whether Alb-HMGB1 -/-tumors exhibit more oxidative damage in the setting of hypoxia and diminished mitochondrial biogenesis, we measured 4-hydroxynonenal (4-HNE) Michael adducts, a marker of oxidative stress. We found a marked increase in formation of 4-HNE in Alb-HMGB1 -/-tumors compared to control (Fig. 5F ). This was associated with decreased expression of the tumor proliferation marker Ki67 and increases in fragmented DNA and expression of cleaved caspase 3, both of which are characteristic of apoptosis ( Fig. 5F; Supporting Fig. S5D) . Altogether, the above results suggest that the loss of HMGB1 in HCC cells results in decreased mitochondrial biogenesis in response to hypoxia, with consequent increased oxidative stress, decreased proliferation, and increased apoptosis. They also suggest that hypoxia and tumor growth act to provide mutually supportive environments in vivo.
HMGB1 INDUCES MITOCHONDRIAL BIOGENESIS IN HYPOXIC CANCER CELLS BY TRANSLOCATING TO THE CYTOPLASM AND ACTIVATING TLR9-DEPENDENT PATHWAYS
We have shown that both in vitro and in vivo hypoxia leads HCC cells to up-regulate PGC-1a expression and mitochondrial biogenesis in an HMGB1-dependent manner. However, the exact intracellular pathways initiated by HMGB1 to induce mitochondrial biogenesis have not been defined. TLR9, a known cytoplasmic receptor for HMGB1, is overexpressed in HCC tumors and is known to promote cancer growth in response to hypoxia. (6, (24) (25) (26) We therefore investigated whether HMGB1 stimulates TLR9 pathways to activate PGC-1a and induce mitochondrial biogenesis. We have shown that HMGB1 translocates from the nucleus to the cytoplasm in hypoxic cancer cells but not in normoxic cells. (6) To confirm this, we subjected Hep1-6 cells to hypoxia and demonstrated that HMGB1 translocates to the cytoplasm, an effect silenced by HMGB1 siRNA (Fig.  6A) . Supporting Fig. S6A confirms our previous observation that HMGB1 associates with TLR9 in Hep1-6 cell lines subjected to hypoxia. (6) PGC-1a activity, and consequently the upregulation of mitochondrial biogenesis, is determined not only by PGC-1a expression levels but also by a number of posttranslational modifications, such as phosphorylation. (27) (28) (29) Figure 6B shows that hypoxia is accompanied by increased phosphorylated PGC-1a (pPGC-1a) in Hep1-6 and Huh7 tumor cells and that this up-regulation is silenced by HMGB1 siRNA. However, activation of TLR9 by the TLR9 agonist markedly up-regulates pPGC-1a even in the presence of HMGB1-specific siRNA. Of note, there were no differences in the levels of PGC-1a phosphorylation in normoxic HCC cells treated with control or HMGB1 siRNA ( Fig. 6B; Supporting Fig. S6B ). Figure 6C demonstrates that stable HMGB1-expressing Hepa1-6 cells displayed a significant increase in activated PGC-1a after hypoxia compared to control cells (phosphorylated green fluorescent protein). Yet, the enhanced effect of pHMGB1 on pPGC-1a expression -/-mice; P < 0.05), respectively. Nuclei (blue), actin (white), PGC-1a/4HNE/Ki67 (red), TUNEL (green). Scale bars, 100 lm; n 5 6 mice/group. Abbreviations: ns, not significant; NT, nontumor liver; T, tumor; TUNEL, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling. 
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in Hep1-6 can be blocked by adding a TLR9 antagonist ( Fig. 6C; Supporting Fig. S6C ). When recombinant HMGB1 (1 lg/lL) was added to the HMGB1 siRNA-treated cells, PGC-1a phosphorylation increased similar to control cells, and thus mitochondrial biogenesis was rescued (Fig. 6C) . Of note, addition of the TLR9 agonist in combination with recombinant HMGB1 to HMGB1-depleted hypoxic cancer cells did not further increase PGC-1a activation as TLR9 receptors may have already been saturated with the recombinant HMGB1 (data not shown). Furthermore, pretreatment of recombinant human HMGB1 with deoxyribonuclease (Roche) did not alter the results of the above experiments, suggesting that it is a direct effect of recombinant human HMGB1 rather than any attached DNA during preparation (data not shown). HMGB1 activation of TLR9 can initiate mitogenactivated protein kinase signaling, (26) and activation of the p38 mitogen-activated protein kinase pathway has been shown to promote PGC-1a expression and mitochondrial biogenesis. (22, 28, 29) Figure 6D shows that hypoxic Hep1-6 cells exhibit an increase in the activation of both p38 and PGC-1a when subjected to hypoxia. Either the silencing of HMGB1 expression or the use of a TLR9 antagonist significantly decreases both p38 and PGC-1a activation (Fig. 6D) . The ability of the TLR9 agonist to activate both p38 and PGC-1a is, however, retained. The levels of PGC-1a expression paralleled the levels of PGC-1a phosphorylation in all of the above experimental groups as evidenced by confocal microscopy (Supporting Fig. S7A ). Furthermore, similar to HMGB1-depleted cells, there was a significant decrease in PGC-1a activation in hypoxic TLR9 siRNA-treated cells compared to cells treated with control siRNA (Supporting Fig. S7B ).
Increased mitochondrial biogenesis in these systems leads to increased mtDNA density and increased cell survival and growth (Fig. 6E,F) . Taken together one can conclude that HMGB1 leaves the nucleus of hypoxic tumor cells and serves as an agonist of cytoplasmic TLR9, which acts with p38 to phosphorylate PGC1a, thereby facilitating mitochondrial biogenesis and cancer cell survival.
Discussion
The death rate in the United States due to HCC is increasing faster than any other type of cancer. (30) The inherent ability of HCC cells to thrive and proliferate despite hypoxic conditions is repeatedly cited as a major reason for this dreadful trend. (6, 31) The ability of some tumors to shift their bioenergetic profile from glycolysis to oxidative phosphorylation in order to satisfy the energetic needs of a rapidly growing population of cells may offer a partial explanation for tumor growth in apparently adverse conditions. Understanding the mechanism by which this energy-generating switch takes place would offer potential therapeutic targets in an area in which medical therapy is now lacking. We have presented here evidence that mitochondrial biogenesis plays a critical role in the ability of HCC cancer cells to survive hypoxia. Both human HCC tumors and HCC cell lines showed evidence of mitochondrial biogenesis by up-regulation of PGC-1a under hypoxic conditions. Furthermore, silencing of PGC-1a in hypoxic HCC cell lines halts proliferation. Mechanistic investigations in vitro indicated that intracellular HMGB1 was essential for increased mitochondrial biogenesis and tumor growth; silencing of HMGB1 in hypoxic HCC cell lines resulted in a significant decrease in PGC-1a activation, mitochondrial biogenesis, oxidative phosphorylation, ATP production, and mitochondrial integrity. Cellular proliferation -1a) was determined in Hepa1-6 and Huh7 cells treated with control or HMGB1 siRNA under normoxic or hypoxic conditions. PGC1-a activation was increased when control HCC cells were subjected to hypoxia but not in HMGB-deficient cells. Adding a TLR9 agonist bypasses the deficiency in HMGB1 and induces PGC-1a expression under hypoxic conditions. (C) Hypoxic pHMGB1 Hep1-6 cells (stable overexpression of HMGB1) showed an increase in pPGC1-a compared to control phosphorylated green fluorescent protein Hep1-6 cells. PGC1-a activation was decreased when pHMGB1 Hep1-6 cells were pretreated with a TLR9 antagonist. The addition of extracellular recombinant HMGB1 increased PGC1-a activation in HMGB1 siRNA-treated hypoxic Hepa1-6 cells. (D) Levels of phosphorylated p38 and PGC1-a were determined for the different groups. p38 phosphorylation and subsequently pPGC1-a were decreased in HMGB1-deficient or TLR9 antagonist-treated cells. Adding a TLR9 agonist rescues the activation of both p38 and PGC1-a in HMGB1-deficient cells. (E) mtDNA content in the different groups after exposure to 24 hours of hypoxia shows an increase in mitochondrial density in the experimental groups that had an increase in PGC1-a activation when subjected to hypoxia. translocates from the nucleus to the cytoplasm and binds to cytoplasmic TLR-9. This binding leads to activation of p38 and subsequent phosphorylation of PGC-1a, with resultant up-regulation of mitochondrial biogenesis. Taken together, our findings suggest that HMGB1 up-regulates mitochondrial biogenesis in HCC cancer cells, promoting tumor survival and proliferation through stimulation of TLR9 signaling pathways (Fig. 7) . Although more studies are required to better understand the role of mitochondrial biogenesis in tumor progression, these results demonstrate that cancer growth under hypoxic conditions is largely dependent on mitochondrial biogenesis and identify HMGB1, TLR9, and PGC-1a as potential targets for therapeutic intervention.
The traditional view about cancer metabolism, namely that it depends on aerobic glycolysis to support the energy requirement for continued growth, requires revision. In order to provide sufficient ATP, some compensatory mechanism is required, especially for solid tumors like HCC that prosper under hypoxic conditions. To meet the energy supply, the cells must increase the number of the mitochondria to produce more ATP. Recently, other researchers have highlighted the crucial role of mitochondrial biogenesis in several different cells facing stress. For instance, hepatocyte survival and maintenance of function in conditions of sepsis or in conditions of ischemia are dependent on mitochondrial biogenesis. (19, 32) Furthermore, mitochondrial biogenesis is an essential repair mechanism tool used by ischemic brain cells. (33) Thus, the elevation of PGC-1a expression and mitochondrial number found in other cells and in HCC cells in our study could also be a mechanism by which the cancer cells attempt to increase their energy output.
As solid tumors grow they create internal and peritumoral areas of hypoxia. Our findings suggest that in zones of tumor hypoxia cancer cells can up-regulate their mitochondrial biogenesis to overcome the harsh environment and offer several advantages needed to pull through and thrive. For example, hypoxic cancer cells can accumulate ROS, which if not cleared, can lead the cancer cell to undergo apoptosis. (34) Our findings suggest that mitochondrial biogenesis is critical to maintain mitochondrial proficiency and the ability to detoxify ROS to increase cancer cell viability during hypoxia. Another advantage is that hypoxic HCC cells can up-regulate their FIG. 7 . Schematic diagram illustrating the proposed role of HMGB1 and TLR9 in activating mitochondrial biogenesis in hypoxic cancer cells. During hypoxia, HMGB1 translocates from the nucleus to the cytoplasm of HCC cells. In the cytoplasm, HMGB1 binds and activates TLR9 receptor. This consequently activates TLR9-associated mitogen-activated protein kinases including p38. This leads to the phosphorylation and activation of PGC1-a. Activated PGC1-a then translocates to the nucleus and binds to NRF, and both act as transcription coactivators of TFAM. TFAM then translocates to the mitochondria to initiate the process of mitochondrial biogenesis. mitochondrial biogenesis to transit to other areas with less hypoxia. LeBleu et al. have shown that by up-regulating mitochondrial biogenesis, mammary epithelial cell lines enhance their migratory and invasive properties. (13) Thus, up-regulation of mitochondrial biogenesis and respiration may represent a mechanism that HCC cells use to form intrahepatic and extrahepatic metastases in more favorable and less hypoxic environments. Increased proliferation also increases tumors' ability to acquire further mutations, which in turn leads to tumor heterogeneity and the emergence of neoantigens with which the host has no immunologic experience. (35) In addition, the changes in the energy profile of cancer cells probably impact the surrounding tumor stroma, which in turn may reciprocally impact the cancer cell's growth. Furthermore, PGC-1a activation and mitochondrial biogenesis can support chemotherapy resistance in colorectal cancer cells, (12) and this may also apply to HCC cells. Tumor heterogeneity could also contribute to chemotherapy resistance encountered in hypoxic tumors in general and HCC specifically. Therefore, further investigations to gain a better understanding of the advantages acquired when HCC cells up-regulate mitochondrial biogenesis is warranted.
These experiments support the hypothesis that HMGB1 signaling is critical to the induction of biogenesis. This is not surprising as this damageassociated molecular pattern protein is known to play a number of pleiotropic roles in inflammation, healing, and cellular biology. (14) HMGB1 can be mobilized and released from the nucleus of cancer cells during hypoxia and pass through the cytoplasm into the peritumoral tissue. (6, 16) In cancer, HMGB1 has been described to play both protumorigenic and antitumorigenic roles. (36) HMGB1 when present in the nucleus stabilizes the chromosomes, maintains telomere length, and can act as an antitumorigenesis protein.
On the other hand, when secreted by cancer cells, extracellular HMGB1 had a predominantly protumorigenic role of stimulating tumor growth and survival by promoting invasion, metastasis, and angiogenesis. (36) Indeed, our lab has shown that HMGB1-induced caspase-1 activation promoted invasion in hypoxia. (16) As mitochondrial biogenesis is also critical for increasing tumor invasiveness, (13) HMGB1 enhances the invasive potential of stressed cancer cells by supplying energy through its cytoplasmic role of upregulating mitochondrial biogenesis and by providing the tools by activating caspase 1 and the downstream effectors through its extracellular function. (16) The role of cytoplasmic HMGB1 in cancer cells had not been adequately defined with regard to tumor behavior. Our experiments demonstrated the dependence of hypoxia-induced biogenesis on cytoplasmic HMGB1 and its receptor TLR9 in cancer cells. In HCC, HMGB1 seems to behave predominantly as a protumorigenic protein both in hypoxic HCC cell lines and in vivo. We also provide further evidence for a mechanism by which HMGB1 contributes to HCC growth, i.e., by activation of endosomal TLR9 signaling to up-regulate mitochondrial biogenesis. Of note, we have shown that during stress mitochondria release DNA (mtDNA) and complex with HMGB1 to activate TLR9 pathways to promote tumor proliferation by activating signal transducer and activator of transcription pathways. (6) In this article, we show that activation of the TLR9 pathways can also induce mitochondrial biogenesis. This brings up an interesting future direction of whether mitochondria themselves can release cytoplasmic signals in the form of mtDNA to activate their own biogenesis.
During hepatic surgery to resect HCC, the liver is routinely subjected to injury due to ischemia resulting from the interruption of the hepatic blood supply that is often necessary to control blood los. (37) The hypoxia resulting may induce mitochondrial biogenesis in micrometastatic intrahepatic metastatic disease and may explain the suboptimal rates of disease-free survival after resection. (38) Death of tumor cells induced by chemotherapy and chemoembolization most likely leads to necrosis, hypoxia, HMGB1 release, mitochondrial biogenesis, and tumor proliferation. Potentially palliative techniques such as ablation by heat, ethanol, or cold depends for its effectiveness on tumor hypoxia; but what may result is mitochondrial biogenesis and more vigorous regrowth. Therefore, the combination of surgery and strategies to block mitochondrial biogenesis may prove to be a promising adjunct treatment to improve outcomes after resection of all but the smallest HCC tumors.
In summary, hypoxia-induced mitochondrial biogenesis in cancer cells, induced by the HMGB1-TLR9 pathway, acts to protect against cell damage and provide a survival mechanism for the cancer cells. Our studies provide insight into uncovered changes in the metabolic program of hypoxic cancer cells that could represent a potential therapeutic target in the fight against cancer.
